This refresh
Data-driven refresh September 8, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,220 tickers); 1,738 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. ADBE — Adobe Inc. · score 88.9
Software - Application · price $257.26 · 1Y $276.58 · 5Y $404.94 · 10Y $600.69
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 14.7x A- · PEG 0.65 A-
Why now. Adobe’s Digital Media subscription engine is fueling a relentless 11.5% YoY revenue growth, while its 62.8% ROE and $10.3B free cash flow give management the latitude to accelerate buybacks and reinvest in the platform, creating a compounding engine that should keep earnings expanding for years. The thesis hinges on the subscription‑driven cash moat that lets Adobe outpace peers and keep margins near the high 28.7% profit margin level.
Moat. The integrated Creative Cloud suite locks in photographers, video editors, designers and marketers on multi‑year contracts, creating switching costs that are hard for rivals to breach. This recurring‑revenue base powers the extraordinary 62.8% ROE, reflecting pricing power from category leadership in digital content creation and the ability to fund share repurchases without eroding balance‑sheet strength.
Risk. A 1.42 beta signals that Adobe’s stock is more volatile than the market, and the Bull Rankings model’s reverse‑DCF shows the current price embeds a zero‑percent free‑cash‑flow growth outlook for a decade—far below the actual 11.5% revenue growth. If growth stalls or margins compress, the high valuation (PE 14.7×) could quickly turn punitive, especially with a debt‑to‑equity of 0.61 that limits flexibility. A sustained slowdown would confirm the bear case and crush the buy‑back catalyst.
Horizon. 1-3 yr $276.58 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $404.94 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $600.69 if current growth sustains into durable earnings power.
2. NBIX — Neurocrine Biosciences, Inc. · score 88.4
Drug Manufacturers - Specialty & Generic · price $155.13 · 1Y $211.72 · 5Y $309.98 · 10Y $459.83
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 22.7x B+ · PEG 0.31 A
Why now. NBIX is poised to compound earnings as its flagship neurological franchise INGREZZA captures expanding tardive dyskinesia and Huntington's disease markets, while Orilissa drives endocrine sales. The business posted 34.4% revenue growth YoY, a 20.9% profit margin, and generated $870 m of free cash flow, all on a modest PE of 22.8 and a PEG of 0.31, indicating the market under‑prices its growth. The thesis rests on sustained pipeline expansion and the ability to reinvest cash into high‑margin specialty drugs that keep the growth engine humming.
Moat. NBIX’s moat stems from deep IP protection and FDA exclusivity on INGREZZA and Oriahnn, locking in neurologic and uterine‑fibroid patients who face high switching costs and limited alternatives. Its low debt‑to‑equity of 0.12 lets the company fund R&D without diluting shareholders, while a near‑20% ROE reflects pricing power in niche, high‑margin specialty categories that competitors can’t quickly replicate.
Risk. The stock trades at an elevated PE of 22.8, implying an 8% annual free‑cash‑flow growth rate that is well below the historic 34.4% revenue surge, suggesting the market may be over‑optimistic about future growth sustainability. A slowdown in INGREZZA uptake or a delayed pipeline read‑through could compress margins, and any adverse regulatory decision would instantly erode the premium. A breach of the 8% implied FCF growth threshold would validate the bear case and topple the bull thesis.
Horizon. 1-3 yr $211.72 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $309.98 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $459.83 if current growth sustains into durable earnings power.
3. HRMY — Harmony Biosciences Holdings, Inc. · score 88.1
Biotechnology · price $42.07 · 1Y $47.36 · 5Y $69.35 · 10Y $102.87
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 13.6x A- · PEG 0.49 A
Why now. Harmony’s commercial‑stage narcolepsy drug WAKIX gives the company a foothold in the U.S. rare‑neurology market, and that platform is now being leveraged into high‑growth pipelines for Prader‑Willi and Myotonic Dystrophy. The business is delivering 24.3% revenue growth YoY, 18.9% profit margin and a PE of 13.7x, all while the Bull Rankings model flags a 94‑point Value pillar as its strongest driver. The thesis rests on compounding cash‑flow expansion from WAKIX and the pipeline, which should keep the free‑cash‑flow trajectory well above the -16% implied by the reverse‑DCF.
Moat. WAKIX’s novel histamine‑H3 antagonism is the only FDA‑approved oral therapy for excessive daytime sleepiness in narcolepsy, creating a high switching cost for patients and neurologists who value its differentiated efficacy. Exclusive U.S. commercial rights and a growing rare‑neurology payer network give Harmony pricing power that underpins its 18.1% ROE, a return driven by a protected franchise rather than commodity pricing.
Risk. The upside hinges on successful Phase 3 results for Pitolisant in Prader‑Willi Syndrome; a setback would strip away the pipeline catalyst that justifies the current valuation. Moreover, the Bull Rankings model’s reverse‑DCF implies a -16% annual free‑cash‑flow growth rate, far below the 24.3% revenue expansion—meaning the market is already pricing in optimistic execution. A miss on the PWS trial or a slowdown in WAKIX uptake would confirm the bear case and force the stock back toward its 52‑week low of $25.52.
Horizon. 1-3 yr $47.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $69.35 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $102.87 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 87.4
Software - Infrastructure · price $14.95 · 1Y $18.70 · 5Y $27.38 · 10Y $40.61
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 22.0x B+ · PEG 0.67 A-
Why now. DLocal’s cross‑border pay‑in platform for global merchants is exploding, delivering 46.6% YoY revenue growth, 18% profit margin and $413 m of free cash flow while scaling on a $4.6 bn market cap. The Bull Rankings model flags a Growth pillar of 98, meaning the business compounds at a rate few peers can match, and the current price already embeds a modest PEG of 0.67. The thesis rests on the relentless expansion of e‑commerce, streaming and ride‑hailing merchants that need DLocal’s unified payment suite.
Moat. The moat lives in DLocal’s end‑to‑end payment stack that aggregates hundreds of local cards, bank transfers and alternative payment methods, locking merchants into a single integration for every market. This breadth creates switching costs and pricing power that fuels a ROE of 34.6%, far above the sector average, and lets DLocal command premium fees on high‑margin cross‑border transactions.
Risk. The biggest headwind is that the reverse‑DCF implies a negative -7% annual free‑cash‑flow growth for the next decade, a stark contrast to the 46.6% revenue surge and suggesting the market may be over‑optimistic about sustainable cash generation. A slowdown in merchant adoption or aggressive pricing wars could force the P/E of 22.8x to compress, confirming the model’s “diluting shareholders” signal and crushing the bull case.
Horizon. 1-3 yr $18.70 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $27.38 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $40.61 if current growth sustains into durable earnings power.
5. PGY — Pagaya Technologies Ltd. · score 86
Software - Infrastructure · price $22.08 · 1Y $28.91 · 5Y $42.33 · 10Y $62.79
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 15.7x A- · PEG 0.04 A
Why now. Pagaya’s Decline Monetization engine is unlocking hidden credit upside for U.S. lenders, driving a 25.6% YoY revenue growth while delivering a 9.1% profit margin and a 19.5% ROE. Coupled with a market‑cap of only $1.9 b and a P/E of 16.3, the stock trades far below the implied 13% negative FCF growth that the reverse‑DCF assumes, meaning the market is under‑pricing the compounding cash‑flow runway. The thesis hinges on scaling Decline Monetization across more loan partners, which should keep the growth engine humming for years.
Moat. The Decline Monetization platform creates a sticky data‑driven network: once lenders feed rejected applications into Pagaya’s AI, they become dependent on its predictive approvals, raising switching costs and locking in recurring fees. This network effect, combined with the proprietary AI that powers Dual Look and First Look, lets Pagaya extract pricing power, reflected in its 19.5% ROE, far above typical software peers.
Risk. A 5.37 beta and a debt‑to‑equity of 1.34 expose Pagaya to market volatility and leverage risk, while the reverse‑DCF’s implied -13% FCF growth suggests analysts are already pricing in aggressive optimism that may not materialise if loan‑originator adoption stalls. A sustained slowdown in revenue growth below the current 25.6% YoY would trigger a re‑rating, confirming the bear case.
Horizon. 1-3 yr $28.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $42.33 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $62.79 if current growth sustains into durable earnings power.
6. FICO — Fair Isaac Corporation · score 85.6
Software - Application · price $933.30 · 1Y $1,464 · 5Y $2,143 · 10Y $3,179
FCF $996m C+ · Rev +24.1% A- · D/E n/a · P/E 27.1x B · PEG 0.65 A-
Why now. The bull case hinges on FICO’s Scores segment, where its predictive credit‑score APIs are baked into billions of transaction streams, fueling a 24.1% revenue growth and a 34.1% profit margin that turns into $996 m of free cash flow. Our Bull Rankings model rates the company 85.6/100 on quality‑growth, with Growth as the strongest pillar, underscoring the durability of this compounding engine. The thesis rests on the continued expansion of credit‑risk analytics across the Americas, EMEA and APAC, which should keep the growth momentum alive.
Moat. FICO’s moat lives in its Scores segment, where banks and fintechs integrate its credit‑scoring models directly into loan origination and fraud‑prevention workflows, creating high switching costs and a data‑network advantage that competitors can’t replicate quickly. The embedded nature of these scores locks in recurring SaaS revenue and sustains the 34.1% margin that powers its cash generation.
Risk. The bear case points to a negative ROE of -19.9% and a beta of 1.32, indicating equity erosion and heightened volatility; the market is already pricing a lofty PE of 27 despite a 24.1% growth rate, suggesting overvaluation. A slowdown in credit‑demand or a successful alternative‑scoring platform would compress margins and could see the stock slide toward its 52‑week low of $870. The key risk trigger is a sustained dip in revenue growth below 20% coupled with widening spreads.
Horizon. 1-3 yr $1,464 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $2,143 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $3,179 if current growth sustains into durable earnings power.
7. INOD — Innodata Inc. · score 85.6
Information Technology Services · price $56.12 · 1Y $122.75 · 5Y $179.72 · 10Y $266.60
FCF $184m C · Rev +39.0% A · D/E 0.02 A- · P/E 43.5x C+ · PEG 0.87 B+
Why now. The bull case hinges on the DDS segment’s AI‑training data engine, which is scaling at a 39% YoY revenue growth and fuels a 14.7% profit margin while generating $184 m of free cash flow; these fundamentals underpin our model’s Growth pillar score of 97 and justify the consensus 1‑yr target of $122.75. The compounding engine is the relentless demand for AI‑ready datasets across tech giants, and as long as that pipeline stays hot, INOD will keep accelerating earnings.
Moat. INOD’s moat lives in its Synodex platform that converts raw medical records into structured data for insurers and healthcare providers—a high‑touch service with deep integration into compliance workflows that creates switching costs and a data‑quality advantage that competitors can’t replicate quickly. Coupled with an ROE of 29.1%, the firm extracts pricing power from its niche expertise in regulated health data and AI model training.
Risk. The bear case centers on the sky‑high valuation: a P/E of 43.1 vastly exceeds the sector average and the Bull Rankings model’s reverse‑DCF shows the current price implies a negative –5% annual free‑cash‑flow growth for the next decade, a stark mismatch to the 39% revenue growth rate. A slowdown in AI spending or a shift to cheaper in‑house data pipelines would force the multiple down, and the beta of 2.88 signals amplified downside in a market pullback. Confirmation would be a sharp price drop toward the 52‑week low of $34.23.
Horizon. 1-3 yr $122.75 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $179.72 at ~26% CAGR — compounding case rests on the competitive position widening. 10 yr $266.60 if current growth sustains into durable earnings power.
8. NVDA — NVIDIA Corporation · score 85.6
Semiconductors · price $225.73 · 1Y $327.13 · 5Y $478.95 · 10Y $710.49
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 28.6x B · PEG 0.59 A-
Why now. NVIDIA’s AI‑centric Compute & Networking platform is locked into the exploding data‑center demand, driving revenue at a staggering 83.4% YoY while delivering a 63.7% profit margin and an eye‑popping 84.2% ROE. Our Bull Rankings model awards an 85.6/100 quality‑growth score, with Growth as the strongest pillar, underscoring the durability of this compounding engine. Even the reverse‑DCF shows the market pricing in a 49% annual free‑cash‑flow expansion—well below the actual revenue surge—meaning the upside is still under‑priced.
Moat. The moat lives in NVIDIA’s data‑center AI infrastructure, where its accelerated‑computing GPUs are the de‑facto standard for hyperscale cloud providers, creating massive switching costs and a virtuous cycle of software‑stack lock‑in. That pricing power fuels the 84.2% ROE, as customers pay premium for performance that rivals cannot match without rebuilding massive ecosystems.
Risk. The stock trades at a lofty PE of 29.2 and a beta of 2.22, exposing investors to valuation compression if AI spend cools or if rivals close the performance gap; a sustained slowdown in data‑center orders would snap the growth trajectory and force the price toward the lower end of the analyst range. A breach of the 52‑week low at $164.27 would confirm that risk.
Horizon. 1-3 yr $327.13 (analyst consensus (n=57)) — fundamentals + valuation re-rating. 5 yr $478.95 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $710.49 if current growth sustains into durable earnings power.
9. ADSK — Autodesk, Inc. · score 85.2
Software - Application · price $212.21 · 1Y $315.37 · 5Y $461.73 · 10Y $684.94
FCF $2.8b B · Rev +17.9% B+ · D/E 1.10 C · P/E 27.5x B · PEG 0.84 B+
Why now. Autodesk’s dominance in construction‑tech, anchored by Autodesk Build and Revit BIM platforms, is fueling a virtuous cycle of subscription revenue and high‑margin cash flow. The business is delivering 17.9% YoY revenue growth, 21.1% profit margin and a massive $2.8B free cash flow run‑rate, all while its subscription model locks in multi‑year contracts. The thesis rests on the continued digital‑transformation of AEC firms, which guarantees compounding earnings as the construction industry deepens its reliance on cloud‑based design and collaboration tools.
Moat. The Revit and BIM Collaborate Pro suites embed Autodesk into the core design workflow of architects, engineers and contractors, creating switching costs that are hard to overcome without massive re‑training and data migration. This lock‑in, combined with a subscription‑based pricing engine, drives the 48.5% ROE by allowing Autodesk to capture pricing power from its category leadership in building information modeling.
Risk. The stock trades at a lofty PE of 27.5 and a beta of 1.31, meaning any slowdown in construction spending or a shift to competing SaaS platforms could compress multiples and amplify volatility. Moreover, a debt‑to‑equity of 1.1 adds leverage risk if cash flows falter. A breach of the 10% FCF growth assumption embedded in the reverse DCF—evidenced by a slowdown in revenue growth—would trigger a sharp re‑rating.
Horizon. 1-3 yr $315.37 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $461.73 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $684.94 if current growth sustains into durable earnings power.
10. APP — AppLovin Corporation · score 84.7
Advertising Agencies · price $312.01 · 1Y $514.48 · 5Y $753.26 · 10Y $1,117
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 24.0x C+ · PEG 0.69 A-
Why now. AppLovin’s MAX in‑app bidding platform is unlocking a virtuous cycle of higher‑margin ad inventory for publishers, driving revenue that is soaring 60.6% YoY and fueling free cash flow of $4.5 B on a razor‑thin PE of 24. The Bull Rankings model gives APP an 84.7/100 quality‑growth score, with Growth as its strongest pillar, confirming that the compounding engine is real and durable. The thesis rests on MAX’s ability to keep expanding its real‑time auction network, which should keep the 31% FCF growth assumption alive for years to come.
Moat. MAX creates a lock‑in effect for app publishers because every impression runs through a real‑time competitive auction that maximizes yield, making it costly for developers to switch to a rival platform. Coupled with Adjust’s measurement suite, AppLovin captures deep user‑level data that fuels better bidding outcomes and sustains its 64.6% profit margin, a clear pricing advantage that competitors can’t replicate quickly.
Risk. The stock trades at a lofty beta of 2.49 and a debt‑to‑equity of 1.11, meaning any market pull‑back or financing strain could erode margins, while the model’s weakest pillar—Value—signals that the current price already embeds a 31% annual FCF growth assumption that may be unrealistic if revenue growth decelerates. A sustained slowdown below the 60.6% YoY rate or a widening of debt would trigger the bear case and break the compounding narrative.
Horizon. 1-3 yr $514.48 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $753.26 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,117 if current growth sustains into durable earnings power.
11. DOCS — Doximity, Inc. · score 84.4
Health Information Services · price $24.42 · 1Y $29.78 · 5Y $43.60 · 10Y $64.67
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 29.1x B · PEG 0.59 A-
Why now. DOCS’s AI‑powered workflow tool Ask locks in U.S. physicians by delivering HIPAA‑compliant evidence at the point of care, turning the platform into a revenue‑generating engine; revenue is climbing 11.2% YoY, profit margins sit at a healthy 25.5%, and free cash flow hits $306 m, all underpinned by our model’s Quality score of 88 – the strongest pillar, proving the business can sustainably compound earnings.
Moat. The moat lives in the physician‑only network and the Ask assistant, which embed Doximity into daily clinical workflows, creating high switching costs; the platform’s pricing power drives an ROE of 18.2%, reflecting the ability to monetize a captive, high‑value audience that rivals can’t replicate quickly.
Risk. The stock trades at a lofty PE of 31.4 while our reverse‑DCF assumes only ~7% annual FCF growth, well below the actual 11.2% revenue growth – a mismatch that could signal over‑optimism; a slip in engagement or a stronger competitor could force the valuation down, and a sustained beta of 1.25 would amplify any market downturn.
Horizon. 1-3 yr $29.78 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.60 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $64.67 if current growth sustains into durable earnings power.
12. CARG — CarGurus, Inc. · score 83.8
Internet Content & Information · price $32.77 · 1Y $41.38 · 5Y $60.59 · 10Y $89.88
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B · P/E 16.9x B+ · PEG 0.72 A-
Why now. CarGurus’ Digital Deal platform is turning its massive dealer network into a high‑velocity, online‑first sales funnel, letting shoppers start purchases before ever stepping on a lot. That engine is feeding a 13.9% YoY revenue growth, a rock‑solid 18.2% profit margin and a $315 m TTM free‑cash‑flow that fuels a 66.6% ROE – a rare combination in a pure‑play internet marketplace. Our Bull Rankings model rates the business at an 83.8 quality‑growth score, with Quality as the strongest pillar, confirming that the moat is real and the growth is sustainable. The thesis rests on the continued scaling of Digital Deal and dealer subscriptions, which should keep compounding earnings for years to come.
Moat. The moat lives in CarGurus’ integrated marketplace that locks dealers into a subscription‑based, data‑rich ecosystem while giving shoppers a single, trusted destination. High ROE (66.6%) stems from pricing power over a captive dealer base that pays for premium visibility and leads, a cost structure competitors can’t duplicate quickly without building a comparable network of inventory and user traffic.
Risk. The downside is that the market is already pricing in aggressive expectations – the reverse‑DCF implies a -5% annual free‑cash‑flow growth, far below the 13.9% revenue expansion we see, and the P/E of 17.4 is high for a growth‑only name. A slowdown in dealer subscription renewals or a dip in margin could push the stock toward its 52‑week low of $26.39, confirming the Bull Rankings model’s weakest pillar, Value.
Horizon. 1-3 yr $41.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $60.59 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $89.88 if current growth sustains into durable earnings power.
13. EXLS — ExlService Holdings, Inc. · score 82.6
Information Technology Services · price $35.52 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 22.5x B+ · PEG 0.95 B+
Why now. The Bull Rankings model gives EXLS a Quality‑Growth score of 82.6, driven by its strongest pillar – Growth – and a solid 13.4% FY revenue expansion across Insurance and Healthcare AI services. Coupled with a stellar ROE of 32.3% and free‑cash‑flow generation of $297 m, the stock trades at a modest 23.2× P/E, implying only ~4% FCF growth in a reverse‑DCF – far below the actual top‑line momentum, leaving ample upside. The thesis rests on the continued compounding of AI‑enabled claims and actuarial analytics revenue.
Moat. EXLS’s AI‑driven claims management and actuarial analytics platform is embedded in large insurers’ core operations, creating high switching costs and data lock‑in. This entrenched position fuels its 32.3% ROE by allowing premium pricing power in the Insurance segment, while the breadth across Healthcare, Banking and International Growth markets diversifies revenue streams and shields against single‑segment disruption.
Risk. At a forward P/E of 23.2, the market may be overpaying for growth that could slow if AI adoption plateaus, and the 0.57 debt‑to‑equity ratio adds leverage risk in a rising‑rate environment. A pullback to the 52‑week low of $24.85 or a margin compression would validate the bear case, eroding the upside baked into the current price.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
14. LRN — Stride, Inc. · score 82.2
Education & Training Services · price $82.15 · 1Y $97.38 · 5Y $142.58 · 10Y $211.50
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 11.5x A · PEG 0.46 A
Why now. The bull case hinges on Stride’s dominant, state‑customized online curriculum platform that locks in K‑12 districts and community colleges, driving a free‑cash‑flow stream of $433 m on a modest $3.5 b market cap and a rock‑solid 20.7% ROE. Coupled with a low 0.33 debt‑to‑equity and ultra‑stable beta of 0.11, the business can reinvest cash into buybacks while compounding earnings. The thesis rests on the platform’s sticky, single‑sign‑on ecosystem that guarantees recurring revenue beyond the modest 4.7% revenue growth rate.
Moat. Stride’s end‑to‑end platform—single sign‑on, LMS, SIS, analytics, and state‑customized curricula—creates high switching costs for school districts that must re‑engineer data flows and compliance reporting to move elsewhere. This lock‑in fuels pricing power, evident in a >20% ROE, and the integrated stack is difficult for generic ed‑tech rivals to replicate quickly.
Risk. The bear case centers on the anemic revenue growth of 4.7% YoY versus the reverse‑DCF’s implied –12% annual free‑cash‑flow expansion, indicating the market is already pricing in aggressive optimism; any slowdown or failure to accelerate growth will crush the valuation narrative. A further red flag is the stock’s proximity to its 52‑week low of $60.61, suggesting limited upside if growth stalls.
Horizon. 1-3 yr $97.38 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $142.58 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $211.50 if current growth sustains into durable earnings power.
15. ADMA — ADMA Biologics, Inc. · score 81.7
Biotechnology · price $9.54 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $116m C · Rev +8.0% B · D/E 1.11 C · P/E 13.6x A- · PEG 0.59 A-
Why now. ADMA’s market‑leading IVIG franchise, anchored by BIVIGAM and ASCENIV, is driving a high‑margin, cash‑generating engine that fuels compounding; the business posted a 33% profit margin, a stellar ROE of 41.4% and free cash flow of $116 m on a $2.1 bn market cap, underscoring durable earnings power. Coupled with a revenue growth of 8% YoY and a low‑beta profile (0.77), the upside hinges on expanding plasma collection capacity and upselling existing immunodeficiency patients. The thesis rests on the relentless cash conversion that lets management buy back shares while the franchise scales.
Moat. ADMA’s moat stems from its vertically integrated plasma collection network and proprietary manufacturing of specialty IVIG products, creating high switching costs for hospitals that rely on consistent, high‑purity plasma supplies. The 41.4% ROE reflects pricing power derived from being one of the few U.S. providers of BIVIGAM and ASCENIV, a position hard for new entrants to replicate given the capital‑intensive collection infrastructure and regulatory hurdles.
Risk. The bear case focuses on the modest 8% revenue growth, which may lag the 4% free‑cash‑flow growth implied by our reverse‑DCF, indicating the market is already pricing in optimistic cash generation; any slowdown in plasma collection or pricing pressure could compress the 33% margin. A debt‑to‑equity of 1.11 adds leverage risk, and the stock trades at a forward P/E of 13.6, leaving little room for error before valuation becomes stretched. A missed quarterly cash‑flow target or a slowdown in buybacks would confirm the downside.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
16. EPAM — EPAM Systems, Inc. · score 81.4
Information Technology Services · price $115.31 · 1Y $122.82 · 5Y $179.83 · 10Y $266.76
FCF $483m C · Rev +10.8% B · D/E 0.04 A- · P/E 15.6x A- · PEG 0.63 A-
Why now. EPAM Systems, a leader in digital platform engineering and AI solutions, presents a compelling growth opportunity at a discounted valuation, reflected in its overall Quality-growth score of 81.4/100. Our model's strongest pillar for EPAM is Value (89/100), reflecting its attractive pricing, with a current P/E TTM of 15.9 and an exceptional PEG Ratio of 0.63. The market is pricing in only ~5%/yr free-cash-flow growth for the next decade, significantly below its reported 10.8% FY YoY revenue growth, indicating substantial pessimism that undervalues its core services in cloud, data, and AI. The crux is the market's mispricing of sustained growth in critical IT services.
Moat. EPAM's durable edge stems from its deep integration into client operations through complex digital platform engineering and specialized cloud services. By providing end-to-end solutions from requirements analysis to cross-platform migration and cybersecurity, EPAM embeds itself as a critical partner, creating high switching costs for clients. Despite our model identifying Quality (74/100) as its weakest pillar compared to sector peers, its consistent delivery in high-demand areas like data, analytics, and artificial intelligence ensures ongoing client reliance and recurring revenue streams.
Risk. Skeptics would point to EPAM's sensitivity to corporate IT spending cycles, evidenced by its Beta of 1.38 and the significant drop from its 52-week high of $222.53 to the current $117.04. While revenue growth is solid at 10.8% FY YoY, the Information Technology Services sector faces constant competitive pressure, which could compress its 7.2% profit margin if demand for digital platform engineering or cloud services softens. A sustained deceleration in client project volume or a material decline in profitability would confirm the bear thesis.
Horizon. 1-3 yr $122.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $179.83 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $266.76 if current growth sustains into durable earnings power.
17. DECK — Deckers Outdoor Corporation · score 81
Footwear & Accessories · price $82.60 · 1Y $122.81 · 5Y $179.81 · 10Y $266.73
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 11.7x A- · PEG 1.05 B+
Why now. Deckers' HOKA performance‑footwear franchise is accelerating premium pricing in the booming outdoor‑active market, delivering 7.9% revenue growth, a 18.4% profit margin and a staggering 44.1% ROE that fuels a $1.1 B free‑cash‑flow engine. Our Bull Rankings model rates the company 81/100 on quality‑growth, with Quality (96) as the strongest pillar, underscoring the durable earnings power, while Growth (74) is the weakest, highlighting the need for continued top‑line expansion. The thesis rests on HOKA’s ability to compound these margins and cash flow as outdoor activity spending stays secularly high.
Moat. Deckers locks in consumers through the HOKA and UGG ecosystems, where product differentiation and proprietary fit technology create high switching costs for athletes and lifestyle shoppers, allowing the firm to command pricing power that translates into the observed 44.1% ROE. The integrated retail and wholesale distribution network further entrenches the brands, making it hard for rivals to replicate the same shelf‑space dominance and consumer loyalty quickly.
Risk. The bear case centers on the modest 7.9% revenue growth versus the market’s expectation of higher expansion, combined with a forward P/E of 12.2 that, while reasonable, still embeds optimism about sustained double‑digit margin expansion; a slowdown in outdoor‑spending or a pricing squeeze could compress margins below the current 18.4%, triggering a sell‑off. Confirmation would be a quarterly miss on revenue growth or margin, pushing the stock back toward its 52‑week low of $78.91.
Horizon. 1-3 yr $122.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $179.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $266.73 if current growth sustains into durable earnings power.
18. RMD — ResMed Inc. · score 79.7
Medical Instruments & Supplies · price $221.05 · 1Y $246.13 · 5Y $360.35 · 10Y $534.56
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 21.2x B+ · PEG 1.33 B
Why now. ResMed’s AirView cloud platform locks hospitals, sleep clinics and home‑care providers into a data‑rich ecosystem that fuels recurring revenue, and that ecosystem is expanding at a 9.9% YoY revenue growth rate while delivering a 26.9% profit margin and a 23.1% ROE. Our Bull Rankings model gives RMD a 79.7 quality‑growth score, with Quality as the strongest pillar, confirming that the business’s high‑margin, data‑driven model compounds earnings. The thesis rests on AirView’s ability to keep customers sticky and drive margin‑expanding growth.
Moat. AirView’s cloud‑connected diagnostics and therapy management create a high switching cost for sleep clinics and hospitals, because clinicians rely on continuous data streams and integrated reporting that competitors cannot replicate overnight. This lock‑in, combined with ResMed’s pricing power in the Sleep and Breathing Health segment, underpins the 23.1% ROE and sustains the premium margins.
Risk. The market is pricing RMD at a lofty PE of 21.9, which exceeds what a 5% free‑cash‑flow growth assumption (the reverse‑DCF implied rate) would justify given the actual 9.9% revenue growth, indicating optimism baked into the price. A slowdown in cloud adoption or a disruptive home‑diagnostic competitor could compress margins and erode the Quality advantage, and a breach of the 0.13 debt‑to‑equity ceiling would signal financial strain. A sustained drop in margin or a missed AirView rollout would confirm the bear case.
Horizon. 1-3 yr $246.13 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $360.35 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $534.56 if current growth sustains into durable earnings power.
19. BSX — Boston Scientific Corporation · score 79.2
Medical Devices · price $44.98 · 1Y $62.69 · 5Y $91.78 · 10Y $136.16
FCF $3.6b B · Rev +13.5% B+ · D/E 0.50 B · P/E 18.2x A- · PEG 0.66 A-
Why now. The bull case hinges on Boston Scientific’s dominant Cardiovascular and MedSurg platforms, especially its single‑use endoscopic scopes that are rapidly winning hospital contracts. The company is delivering 13.5% revenue growth YoY, backed by a robust $3.6 B free‑cash‑flow run‑rate and a low 0.5 debt‑to‑equity ratio, while our model’s strongest pillar – Growth – scores 88, underscoring a high‑quality compounder. The thesis rests on the ability to keep compounding earnings at double‑digit rates as the minimally invasive market expands.
Moat. Boston Scientific’s moat lives in its entrenched relationships with interventional cardiologists and gastroenterologists who rely on its proprietary delivery systems and single‑use duodenoscopes—devices that require extensive clinical validation and regulatory clearance, creating high switching costs. The MedSurg segment’s infection‑prevention portfolio further locks in hospitals that value bundled, proven solutions, reinforcing pricing power and protecting margins.
Risk. The bear case centers on the fact that the market is already pricing in a pessimistic free‑cash‑flow outlook – a reverse‑DCF implies a –2% annual FCF growth over ten years – despite the company posting a healthy 17.5% profit margin and a modest PE of 18.2. If revenue growth stalls below the current 13.5% pace or margin pressure intensifies from competitive pricing, the stock could slide toward its 52‑week low of $42.2. A sustained slowdown would validate the negative growth assumption and crush the bull thesis.
Horizon. 1-3 yr $62.69 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $91.78 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $136.16 if current growth sustains into durable earnings power.
20. CPAY — Corpay, Inc. · score 79.2
Software - Infrastructure · price $407.05 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 24.7x B+ · PEG 0.80 A-
Why now. Corpay’s corporate payments platform is rapidly becoming the default spend‑management solution for mid‑size enterprises, driving a 20.4% YoY revenue growth and a 22.7% profit margin that fuels a ROE of 32.2%. The Bull Rankings model gives the name a Quality‑Growth score of 79.2, with Growth as its strongest pillar, underscoring the durability of this compounding engine. With a PEG of 0.8 and a buy‑back program, the market is already pricing in a modest 3% FCF growth, far below the real growth trajectory – the upside rests on the business continuing to expand its cross‑border and virtual‑card offerings.
Moat. The moat lives in Corpay’s integrated AP‑modernization suite and virtual‑card ecosystem, which lock large corporate treasuries into a single spend‑control platform. High‑margin, recurring fees and a 32.2% ROE stem from pricing power in the corporate payments niche, where switching costs are steep because clients must re‑engineer their entire procurement workflow to move away from Corpay’s network.
Risk. The bears point to a debt‑to‑equity ratio of 2.75 and a forward‑looking P/E of 24.7, suggesting the stock is priced for continued acceleration that may be hard to sustain if competitive pressure forces margin compression. A slowdown in corporate travel or vehicle‑related spend would hit the Lodging and Vehicle Payments segments hard, and a breach of the 3% implied FCF growth in the reverse‑DCF would trigger a sharp re‑rating.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
21. DXCM — DexCom, Inc. · score 79.2
Medical Devices · price $84.53 · 1Y $94.12 · 5Y $137.80 · 10Y $204.42
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 33.4x C+ · PEG 1.35 B
Why now. DexCom’s G7 platform is cementing its dominance in the U.S. CGM market, driving a 15.5% YoY revenue growth while delivering a 20.1% profit margin and a stellar 38.1% ROE. Coupled with a 22% implied free‑cash‑flow growth in our reverse‑DCF, the stock is poised to compound earnings as G7 and the new G7 15‑Day expand into the growing pre‑diabetes segment. The thesis rests on sustained adoption of the G7 system across endocrinologists and patients.
Moat. DexCom’s moat lies in its integrated CGM ecosystem—G7 hardware, the Share remote‑monitoring service, and the Follow app—locked to endocrinologists and diabetes clinics, creating high switching costs and pricing power that fuels a 38.1% ROE. The company’s FDA‑cleared, 15‑day sensor extension further entrenches patients, while its direct‑to‑provider distribution limits competitor encroachment.
Risk. The stock trades at a lofty 33.4× forward P/E and a beta of 1.42, signaling market expectations that may outpace the 15.5% revenue growth rate; any slowdown in G7 adoption or aggressive pricing pressure from rivals would compress margins and erode the 20.1% profit margin. A breach of the 22% free‑cash‑flow growth assumption would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $94.12 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $137.80 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $204.42 if current growth sustains into durable earnings power.
22. YUMC — Yum China Holdings, Inc. · score 78.5
Restaurants · price $43.34 · 1Y $62.05 · 5Y $90.85 · 10Y $134.77
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 15.9x B+ · PEG 0.97 B+
Why now. Yum China’s KFC and Pizza Hut franchise network is rapidly scaling its online delivery footprint, driving a 8.8% revenue growth while generating $940 m of free‑cash‑flow and a solid 7.8% profit margin. Our Bull Rankings model awards a 78.5 quality‑growth score, with Quality (85) as the strongest pillar, confirming the business’s high‑margin, repeat‑customer engine, while the modest Value score (75) flags pricing power as the key upside driver. The reverse‑DCF shows the market is pricing only ~5% FCF growth versus the 8.8% top‑line growth we see, meaning the current $43.60 price already embeds a conservative outlook – the compounding power of its delivery‑centric KFC/Pizza Hut model is the engine that will lift the stock to the consensus $62.05 target.
Moat. Yum China’s moat stems from its exclusive rights to operate KFC, Pizza Hut, Taco Bell and other concepts across China, coupled with an integrated online delivery platform that locks in urban diners and reduces churn. The franchise model delivers a 18.2% ROE, reflecting pricing power that stems from category leadership in fast‑food and casual dining, a network that rivals cannot replicate quickly in China’s fragmented restaurant landscape.
Risk. The bear case hinges on a slowdown in the Chinese quick‑service market; if revenue growth falls below the 5% FCF growth baked into today’s price, margins could compress from the current 7.8% and the stock could tumble toward its 52‑week low of $40.15. A widening debt‑to‑equity ratio or a P/E drift above the sector‑average 16 would be the first concrete signal that the growth story is unraveling.
Horizon. 1-3 yr $62.05 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $90.85 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $134.77 if current growth sustains into durable earnings power.
23. META — Meta Platforms, Inc. · score 77.6
Internet Content & Information · price $613.48 · 1Y $754.77 · 5Y $1,105 · 10Y $1,639
FCF $41.0b A · Rev +27.7% A- · D/E 0.43 B+ · P/E 23.1x B · PEG 0.82 B+
Why now. Meta’s Family of Apps is set to keep compounding revenue as its global user base deepens engagement, driven by 27.7% YoY revenue growth, a 29.8% profit margin and $41.0b of free cash flow that fuels reinvestment and buybacks. The Bull Rankings model scores Growth at 92, the strongest pillar, confirming that the business’s high‑margin ad engine can sustain acceleration, while the reverse‑DCF shows the market already assumes a lofty 33% FCF growth—a premium that leaves little upside if growth stalls. The thesis hinges on the FoA segment’s ability to keep monetizing its massive network effects at these rates.
Moat. Meta’s moat lives in the entrenched network of Facebook, Instagram and Messenger, where each additional user amplifies ad inventory and data richness, creating a self‑reinforcing loop that competitors can’t replicate quickly. The 26.1% ROE reflects pricing power from category leadership in social advertising, turning massive scale into superior returns on capital.
Risk. The bear case centers on the market pricing Meta at a premium P/E of 23.3 while the reverse‑DCF demands 33% annual FCF growth—far above the 27.7% revenue pace, exposing a valuation gap if ad spend slows or competition erodes margins. A slip in profit margin or a rise in debt‑to‑equity above 0.43 would validate the over‑optimism, and a sustained beta of 1.24 could amplify downside on broader market turbulence.
Horizon. 1-3 yr $754.77 (analyst consensus (n=57)) — fundamentals + valuation re-rating. 5 yr $1,105 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $1,639 if current growth sustains into durable earnings power.
24. CI — The Cigna Group · score 77
Healthcare Plans · price $275.83 · 1Y $341.42 · 5Y $499.87 · 10Y $741.52
FCF $9.1b B+ · Rev +11.3% B · D/E 0.74 C+ · P/E 11.4x A · PEG 0.77 A-
Why now. Cigna’s Evernorth Pharmacy Benefit Services is the engine driving an 11.3% FY revenue growth while delivering $9.1B of free cash flow and trading at a rock‑bottom PE of 11.4, a valuation gap the market can’t ignore. The Bull Rankings model scores CI 77/100 on quality‑growth, with Value as its strongest pillar, confirming that the cheap multiple is the primary catalyst. The thesis hinges on the PBM’s ability to keep expanding its whole‑person health contracts, compounding cash flow at double‑digit rates.
Moat. Evernorth’s integrated pharmacy‑benefit platform locks in large employer and health‑plan customers through a proprietary network of retail and specialty pharmacies, drug formulary expertise and home‑delivery logistics that competitors can’t replicate quickly. This scale fuels a 16.8% ROE, reflecting pricing power and cost efficiencies that protect margins despite a low‑beta (0.32) environment.
Risk. The business’s razor‑thin 2.3% profit margin and a debt‑to‑equity of 0.74 expose it to any adverse regulatory or drug‑price pressure, while the Bull Rankings model flags Quality as its weakest pillar, warning that execution risk could erode earnings. A margin contraction or a rise in debt would validate the bear case and crush the upside.
Horizon. 1-3 yr $341.42 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $499.87 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $741.52 if current growth sustains into durable earnings power.
25. WMG — Warner Music Group Corp. · score 76.9
Entertainment · price $28.03 · 1Y $36.88 · 5Y $54.00 · 10Y $80.10
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 22.4x B · PEG 0.52 A-
Why now. Warner Music’s explosive 12.9% revenue growth and a razor‑thin PEG of 0.52 make its 78.7% ROE a self‑reinforcing engine, while the newly announced dividend hike signals confidence in cash generation. The company’s $836 m free‑cash‑flow runway fuels both buybacks and reinvestment in its two‑million‑song catalog, ensuring compounding earnings for years to come. The thesis rests on the growth pillar of our model staying alive through relentless hit‑making and publishing royalties.
Moat. WMG owns and licenses a two‑million‑song catalog across Recorded Music and Music Publishing, giving it exclusive rights to stream, sync and reissue hits that competitors cannot replicate without costly acquisitions. This IP moat drives pricing power, evident in a staggering 78.7% ROE, as every new placement extracts premium revenue from a locked‑in library of evergreen content.
Risk. The balance sheet’s 4.53 debt‑to‑equity ratio and a beta of 1.3 amplify downside if the music‑streaming market cools or licensing fees contract, while a forward P/E of 23 already prices in high growth expectations. A slip in revenue growth below the current 12.9% or a widening of debt would validate the bear view, and a dividend cut would be the decisive trigger that shatters the bull case.
Horizon. 1-3 yr $36.88 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $54.00 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $80.10 if current growth sustains into durable earnings power.
26. VRT — Vertiv Holdings Co · score 76
Electrical Equipment & Parts · price $290.83 · 1Y $338.15 · 5Y $495.09 · 10Y $734.43
FCF $2.9b B · Rev +26.2% A- · D/E 0.70 B · P/E 65.7x D · PEG 0.95 B+
Why now. Vertiv’s dominance in data‑center critical power and thermal management fuels a compounding revenue engine – its 26.2% FY YoY revenue growth is underpinned by a booming demand for modular UPS and liquid‑cooled thermal solutions. The business converts that growth into high‑margin cash, delivering a 15.1% profit margin and a robust $2.9B free‑cash‑flow run‑rate, which our model translates into a 45% annual FCF growth assumption. The thesis rests on the relentless expansion of hyperscale and edge data‑center capacity that only Vertiv’s integrated power‑and‑cooling platforms can supply.
Moat. Vertiv’s moat stems from its end‑to‑end critical infrastructure suite – single‑phase UPS, rack power distribution, and liquid‑cooled thermal systems – that lock customers into long‑term service contracts and high switching costs. Its ROE of 36.4% reflects pricing power derived from category leadership in modular data‑center solutions, a capability rivals cannot replicate quickly because it requires deep engineering, global service networks, and certified safety compliance.
Risk. The bear case hinges on the lofty valuation: a forward P/E of 63.3 is far above sector averages, and the implied 45% FCF growth far outstrips the realistic revenue pace of 26.2%, leaving little margin for a slowdown. A beta of 2.08 amplifies market volatility, and any slowdown in data‑center capex or a shift to cheaper, commodity‑grade power solutions would compress margins and test the high leverage (Debt/Equity 0.7). A sustained miss on growth would push the stock back toward its 52‑week low of $120.83, confirming the downside.
Horizon. 1-3 yr $338.15 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $495.09 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $734.43 if current growth sustains into durable earnings power.
27. MELI — MercadoLibre, Inc. · score 75.9
Internet Retail · price $1926.25 · 1Y $2,265 · 5Y $3,316 · 10Y $4,919
FCF $12.4b A- · Rev +41.2% A · D/E 1.69 C+ · P/E 52.3x D · PEG 0.96 B+
Why now. MercadoLibre’s Mercado Pago fintech platform is the engine of compounding, feeding a 41.2% YoY revenue surge and a $12.4 B free‑cash‑flow haul that fuels both marketplace expansion and credit‑line growth; the 23.8% ROE proves the business converts that scale into superior returns. With a PE of 53.8× and a PEG of 0.96, the market already prices in high‑growth expectations, but the core driver—digital payments embedded in every transaction—will keep the growth engine humming for years. The thesis rests on Mercado Pago’s ability to lock more sellers and buyers into its ecosystem, sustaining the revenue‑growth runway.
Moat. The moat lives in the two‑sided network of Mercado Libre Marketplace and Mercado Pago: sellers need the payment rails to reach buyers, while buyers rely on seamless checkout and credit options. This creates a high switching cost and a virtuous loop that lifts gross margins, reflected in the 23.8% ROE, and lets MercadoLibre price‑discriminate and cross‑sell services faster than any new entrant could replicate.
Risk. The stock trades at a lofty 53.8× PE and a beta of 1.31, meaning any slowdown in the 41.2% revenue growth or a dip in profit margins would crush valuation multiples. A debt‑to‑equity of 1.69 adds financial leverage risk if cash conversion falters. Moreover, the Bull Rankings model’s reverse‑DCF shows the current price implies a -7% annual FCF growth for the next decade—an unrealistic optimism that would be busted if growth decelerates, triggering a sharp price correction.
Horizon. 1-3 yr $2,265 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,316 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $4,919 if current growth sustains into durable earnings power.
28. EME — EMCOR Group, Inc. · score 75.5
Engineering & Construction · price $773.16 · 1Y $1,033 · 5Y $1,513 · 10Y $2,244
FCF $1.2b C+ · Rev +18.9% B+ · D/E 0.13 A- · P/E 24.1x B+ · PEG 0.31 A
Why now. EMCOR’s dominance in power‑transmission and data‑communications construction fuels a compounding engine: revenue is surging +18.9% YoY, free cash flow tops $1.2 B, and ROE sits at a blistering 35.3%. Coupled with a modest 0.13 debt‑to‑equity and a PEG of 0.31, the business is set to reinvest cash into higher‑margin, long‑term service contracts that keep earnings expanding. The whole thesis hinges on sustaining this high‑margin growth cycle.
Moat. EMCOR locks in multi‑year, capital‑intensive contracts for utility and data‑center customers, creating switching costs that deter rivals; its integrated design‑to‑maintenance platform lets it command pricing power, reflected in a 35.3% ROE. The blend of electrical, mechanical, and HVAC expertise across the U.S. and U.K. makes it the go‑to partner for complex infrastructure, a capability hard to replicate quickly.
Risk. The market is already pricing aggressive optimism: a forward PE of 24.1 implies a reverse‑DCF growth of ~23% FCF annually, well above the 18.9% revenue pace and potentially unsustainable if margins slip from the current 7.7%. A beta of 1.13 adds volatility, and any slowdown in utility spending would compress earnings, confirming the bear case.
Horizon. 1-3 yr $1,033 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $1,513 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $2,244 if current growth sustains into durable earnings power.
29. STRL — Sterling Infrastructure, Inc. · score 75.4
Engineering & Construction · price $502.20 · 1Y $876.00 · 5Y $1,283 · 10Y $1,903
FCF $482m C · Rev +60.8% A · D/E 0.24 A- · P/E 36.2x C+ · PEG 0.60 A-
Why now. The bull case hinges on STRL’s dominant E‑Infrastructure Solutions franchise, which is winning multi‑year contracts to build e‑commerce distribution centers and data centers for blue‑chip tenants. That franchise is fueling a 60.8% YoY revenue growth, while the company converts that top‑line surge into a 12.5% profit margin and a $482 M free‑cash‑flow run‑rate. Our Bull Rankings model awards a 75.4/100 quality‑growth score, with Growth as the strongest pillar, underscoring the durability of this compounding engine. The thesis rests on the continuation of this high‑growth, high‑margin cycle.
Moat. STRL’s moat derives from its deep relationships with blue‑chip e‑commerce and data‑center operators, who face high switching costs and stringent uptime requirements; STRL’s integrated site‑development expertise across permitting, utility design, and construction creates a cost advantage that competitors can’t replicate quickly. This advantage translates into an ROE of 31.8%, reflecting pricing power and efficient capital deployment in a niche where execution risk is a key differentiator.
Risk. The bear case centers on the lofty valuation: a PE of 35.1x and a beta of 1.85 imply that any slowdown in the e‑infrastructure pipeline or a macro‑driven cut in capex could trigger a sharp price correction. If revenue growth falls back from the current 60.8% pace, the reverse‑DCF implied 39% FCF growth becomes untenable, and the stock could retreat toward its 52‑week low of $280.81. A sustained dip in margin or a rise in debt‑to‑equity above the current 0.24 would confirm the downside.
Horizon. 1-3 yr $876.00 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $1,283 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,903 if current growth sustains into durable earnings power.
30. CCK — Crown Holdings, Inc. · score 75.3
Packaging & Containers · price $113.23 · 1Y $136.57 · 5Y $199.95 · 10Y $296.62
FCF $1.2b C+ · Rev +10.3% B · D/E 1.86 C+ · P/E 16.3x B+ · PEG 0.64 A-
Why now. Crown’s dominant position in recyclable aluminum beverage cans fuels a virtuous growth loop: the Americas Beverage segment is expanding as brewers and soft‑drink makers shift to sustainable packaging, driving revenue up 10.3% YoY. Management converts that top‑line momentum into cash, delivering $1.2 B of free cash flow and a razor‑thin PE of 16.3× that rewards earnings growth. With a stellar ROE of 27.3%, the company compounds earnings at a rate that outpaces peers, and the bull case hinges on this compounding staying alive as the global cans market continues to green‑up.
Moat. The moat lives in Crown’s deep‑rooted relationships with major beverage brands that require custom‑engineered aluminum cans and caps—products that are costly to re‑tool for rivals. Its high ROE stems from pricing power in the beverage‑can niche, where switching costs are high because customers lock in long‑term supply contracts and rely on Crown’s proven tooling and rapid‑turnaround equipment.
Risk. The bears point to the company’s leverage—debt‑to‑equity sits at a lofty 1.86—limiting financial flexibility if a downturn hits the beverage sector. Moreover, our reverse‑DCF shows the current price embeds a -14% annual free‑cash‑flow growth assumption, starkly at odds with the actual 10.3% revenue growth, suggesting the market may be over‑optimistic. A credit downgrade or a slowdown in beverage‑can demand would validate this risk and crush the bull thesis.
Horizon. 1-3 yr $136.57 (analyst consensus (n=14)) — fundamentals + valuation re-rating. 5 yr $199.95 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $296.62 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.